Michelle Xia
$1.3B
Born
Nov 01, 1966
Age
59
Source of Wealth
Biotech
Residence
Zhongshan,
Citizenship
United States
Marital Status
Children
0
Education
- Michelle Yu Xia is cofounder, chairwoman and CEO of China-based biotech firm Akeso, which has multiple approved drugs in China to treat cancer.
- Akeso has captured attention in the biotech world because one of its drugs outperformed Merck's bestseller Keytruda in a head to head Phase 3 trial in 2024.
- The success of that Akeso drug, ivonescimab, drove up the price of Akeso's shares; the company is listed on the Hong Kong Stock Exchange.
- Prior to Akeso, Xia worked in research and at U.S. biotech firms for a dozen years starting in the mid 1990s and obtained U.S. citizenship while in America.
- Akeso licensed its most promising cancer drug to Miami-based firm Summit Therapeutics in 2022 for markets including the U.S., Europe and Japan.
| Exchange | Ticker | Company Name | Number Of Shares | Share Price | Currency Code |
|---|